Document is current
Any future updates will be listed below
-
Authors
Ghesquières, Hervé https://orcid.org/0000-0002-3131-3718
Drouet, Youenn
Slager, Susan L. https://orcid.org/0000-0002-5173-4712
Morschhauser, Franck
Julia, Edith https://orcid.org/0000-0003-3325-8107
Galimberti, Sara
Robinson, Dennis
Larson, Melissa C.
Testard, Quentin
Tesson, Bruno
Deleuze, Jean-François
Boland, Anne
Thomas, Emilie
Lasset, Christine
Novak, Anne J. https://orcid.org/0000-0002-7904-1651
Xerri, Luc
Luminari, Stefano https://orcid.org/0000-0001-8446-2285
Verney, Aurelie
Laurent, Camille
Rimsza, Lisa M.
Habermann, Thomas M. https://orcid.org/0000-0003-3532-9132
Federico, Massimo
Link, Brian K.
Salles, Gilles https://orcid.org/0000-0002-9541-8666
Cerhan, James R. https://orcid.org/0000-0002-7482-178X
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb
U.S. Department of Health & Human Services | National Institutes of Health (P30 CA008748)
U.S. Department of Health & Human Services | National Institutes of Health (P50 CA97274, U01 CA195568)
- License Information
-
More Information
Article History
Received: 13 June 2025
Revised: 25 November 2025
Accepted: 12 December 2025
First Online: 9 January 2026
Competing interests
: HG declares the following competing interests: consultancy, Roche, BMS, Takeda; honoraria, Gilead, Roche, BMS, AbbVie, Takeda. FM declares the following competing interests: consultancy, Roche/Genentech; consultancy and membership on an entity’s Board of Directors or advisory committees, Kite/Gilead Sciences, Bristol Myers Squibb, AbbVie, Epizyme, AstraZeneca, Novartis, Genmab; honoraria, Roche/Genentech, Chugai, Takeda. SL declares the following competing interests: advisory board, Roche, Beigene, Incyte, Regeneron, Kite, Novartis, BMS, AbbVie, Sobi, Takeda; research funding, Beigene. Other authors declare no competing interests.
: PRIMA, RELEVANCE, and FOLL05 were approved by the Ethics Committees of Lyon B (France), Nord-Ouest IV (France), and Modena (Italy), respectively. The MER was approved by the Human Subjects Review Boards at Mayo Clinic and the University of Iowa. This FL GWAS study performed with these four cohorts was approved by the Hospices Civils de Lyon (HCL) Ethics Committee (French data protection authority, CNIL register number 17-165) and is registered at (NCT03234140). Materials from patients were collected after written informed consent according to the Declaration of Helsinki. Experiments were conducted in accordance with institutional and national guidelines.
